CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services. Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway. The new services will incorporate the Company’s advanced Liver-on-Chip™ technology, and expertise in the field to enable researchers to generate predictive and human-relevant data, improving the translatability from discovery to clinic, and accelerating new drugs to market. Based on the success of CN Bio’s Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Fee-For-Service offerings, the new toxicity testing services also provide researchers with additional support and bandwidth during the COVID-19 pandemic, when laboratories are not at full capacity. Similarly to the NAFLD/NASH Fee-For-Service, all studies use the Company’s PhysioMimix™ Organ-on-Chip system and in vitro 3D Liver-on-Chip™ model; replicating the physiological and mechanical microenvironment of the liver to fast-track lead targets and generate actionable data in weeks that is reproducible, and cost-effective versus animal studies. CN Bio’s extended portfolio of services offers solutions to many existing workflow challenges including: drug metabolism testing, to study the human metabolism of lead candidates, identify metabolites and correlation with cell health – even for low clearance compounds, and safety toxicity testing, to provide in-depth analysis of acute or chronic drug-induced liver injury using a wide range of endpoints to determine causality and mechanism of toxicity. The Company also provides complimentary service capabilities to support industry and biotechnology organisations that have been impacted by the COVID-19 pandemic. Read more